April 5, 2019

In May, U.S.-based Abbott Labs secured the top spot in India’s growing pharmaceutical industry with its US$ billion takeover of Piramal. In , Ajay Piramal promoted Piramal Healthcare sold off its main formulation business to Abbott India for over INR 17, crore and announced a buy-back of . When US-based global health care major Abbott acquired the formulations business of Piramal Healthcare in a $billion deal in , it had.

Author: Voodoom Judal
Country: Mauritius
Language: English (Spanish)
Genre: Health and Food
Published (Last): 13 April 2018
Pages: 143
PDF File Size: 2.28 Mb
ePub File Size: 4.3 Mb
ISBN: 510-1-67420-766-7
Downloads: 35884
Price: Free* [*Free Regsitration Required]
Uploader: Akim

All the same, the West continues to dominate pharmaceutical innovation, and companies in India and other emerging markets could play a supportive role, according to Danzon.

Abbott to pay $ billion for unit of India’s Piramal | Reuters

Bringing the bazaars home. Danzon points to Dr.

Globally, Abbott also faces the pressure of playing catch-up with its bigger rivals. It makes a lot of sense if they can pull off all the integration issues. In fact, 10 days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila. White, chairman and chief executive officer, Abbott. Out of which, INR 2, crore was used for buy-back of shares.

Indian companies can hope to become truly global pharmaceutical companies only through drug discovery, says Piramal. In the years sincePirmal Enterprises has proved adept at taking advantage of opportunities for its cash.

Featured Today In Travel. According to Ranjit Kapadia, the Abbott-Piramal and Daiichi-Ranbaxy deals will increase the significance of Indian assets in the future.

Abbott to pay $3.7 billion for unit of India’s Piramal

BOis booming as governments battle rising healthcare costs. The business that will continue to be under Piramal include custom manufacturing for third parties, critical care, over the counter consumer products, manufacture and supply of active pharmaceutical ingredients APIvitamin and fine chemicals, diagnostic medical devices and equipment and dignostic services and clinical resreach services.


The hunter has become the hunted. Food and Drug Administration said in February Ranbaxy sold misbranded or adulterated drugs in the United States, its largest market, having earlier banned imports of over 30 generic drugs from the firm. Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western and emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business India.

Buy-back was took place in two tranches: The potential to expand with very high priced specialty products is seriously limited. More than one voice suggested the company return a part of the cash to its shareholders. Ajay Piramal, however, reiterated that he was not exiting the business. As quantum of funds was available that time for existing businesses, The company decided to diversify into new businesses. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Three main businesses remained immediately after divestiture was: Abbott, which is celebrating its th year in India, has more than 2, employees across all of its businesses there.

PEL bought back But new Wharton research provides pira,al insight into the benefits of PE buyouts. Help us delete comments that do not follow these guidelines by marking them offensive. Its Pharma Solutions Custom Manufacturing business recorded sales of Rs crore for the last year as compared to Rs crore during FY as result of closure of its manufacturing facility at Huddersfield, UK.

But the deal takes them to the number one slot, he adds. BOas global drugmakers look to boost their presence in emerging markets. You have to create a whole organization, and that takes time. Making women feel complete again. Now, Piramal on deall own has that opportunity. Related Videos ET Now: Sumeet ChatterjeeBharghavi Nagaraju.


That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing. As on 31 st March 54 33 Market Cap 7, Log In or sign up to comment. These other players are not even interested in doing that.

Refrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. According to Reuters, Abbott was advised by Morgan Stanley. The 10 big questions for – Part 2. Abboott year of the last action hero. Based in Abbott Park, Ill. India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon.

To verify, just follow the link in the message.

A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?

Abbott, which will fund the transaction with cash on the balance sheet, says, the deal will be conducted through its wholly-owned subsidiary.

The Thomson Reuters Trust Principles. The property lending business through Piramal Fund Management has seen its book bulge to Rs 8, crore.

Its other businesses include third-party manufacturing and pathology laboratories. A key differentiator here is pramal unlike in the U.